These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 1795000)

  • 1. Ambulatory high-dose 5-day continuous-infusion ifosfamide combination chemotherapy in advanced solid tumors: a feasibility study.
    Loeffler TM; Weber FW; Hausamen TU
    J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S125-8. PubMed ID: 1795000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ambulatory continuous infusion ifosfamide with oral etoposide in advanced sarcomas.
    Skubitz KM; Hamdan H; Thompson RC
    Cancer; 1993 Nov; 72(10):2963-9. PubMed ID: 8221562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioavailability of subcutaneous ifosfamide and feasibility of continuous outpatient application in cancer patients.
    Cerny T; Küpfer A; Zeugin T; Brunner KW
    Ann Oncol; 1990 Sep; 1(5):365-8. PubMed ID: 2124500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subcutaneous continuous infusion of ifosfamide and cyclophosphamide in ambulatory cancer patients: bioavailability and feasibility.
    Cerny T; Graf A; Rohner P; Zeugin T; Brunner KW; Küpfer A
    J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S129-34. PubMed ID: 1795001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dosing and side-effects of ifosfamide plus mesna.
    Brade WP; Herdrich K; Kachel-Fischer U; Araujo CE
    J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S164-86. PubMed ID: 1795007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule.
    Serrone L; Zeuli M; Gamucci T; Nardi M; Cognetti F
    Cancer Chemother Pharmacol; 2001 Mar; 47(3):206-10. PubMed ID: 11320663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose finding of ifosfamide administered with a chronic two-week continuous infusion.
    Cartei G; Clocchiatti L; Sacco C; Pella N; Bearz A; Mantero J; Pastorelli D; Salmaso F; Zustovich F
    Oncology; 2003; 65 Suppl 2():31-6. PubMed ID: 14586144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ambulatory 4-day continuous-infusion schedule of high-dose ifosfamide with mesna uroprotection and granulocyte colony-stimulating factor in advanced solid tumours: a phase I study.
    Toma S; Palumbo R; Comandone A; Oliva C; Vincenti M; Bumma C; Rosso R
    Ann Oncol; 1995 Feb; 6(2):193-6. PubMed ID: 7540421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ambulatory treatment with 5 days continuous venous infusion of ifosfamide for advanced colorectal cancer: a phase II feasibility study.
    Focan C; Kreutz F; Levi F
    Anticancer Drugs; 1993 Aug; 4(4):459-62. PubMed ID: 8400348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paclitaxel by 72-hour continuous infusion followed by bolus intravenous ifosfamide or epirubicin: results of two phase I studies.
    Miglietta L; Marenghi C; Nizzo R; Foglia G; Ragni N; Boccardo F
    Oncology; 2001; 60(2):116-22. PubMed ID: 11244325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study of high-dose ifosfamide and escalating doses of carboplatin with autologous bone marrow support.
    Elias AD; Ayash LJ; Eder JP; Wheeler C; Deary J; Weissman L; Schryber S; Hunt M; Critchlow J; Schnipper L
    J Clin Oncol; 1991 Feb; 9(2):320-7. PubMed ID: 1846407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ifosfamide- and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma.
    Mayer J; Vásová I; Korístek Z; Navrátil M; Klabusay M; Doubek M; Vorlícek J; Cernilová I; Vodvárka P; Petráková K
    Eur J Haematol Suppl; 2001 Jul; 64():21-7. PubMed ID: 11486396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A retrospective study of treatment and prophylaxis of ifosfamide-induced hemorrhagic cystitis in pediatric and adolescent and young adult (AYA) patients with solid tumors.
    Saito Y; Kumamoto T; Makino Y; Tamai I; Ogawa C; Terakado H
    Jpn J Clin Oncol; 2016 Sep; 46(9):856-61. PubMed ID: 27380806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules.
    Antman KH; Elias A; Ryan L
    Semin Oncol; 1990 Apr; 17(2 Suppl 4):68-73. PubMed ID: 2110386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pilot study of ambulatory infusional delivery of a multidrug regimen: ifosfamide, carboplatin and etoposide (ICE).
    Lokich J; Anderson N; Moore C; Bern M; Coco F; Dow E
    J Infus Chemother; 1996; 6(1):39-42. PubMed ID: 8748006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dose escalation of the hypoxic cell sensitizer etanidazole combined with ifosfamide, carboplatin, etoposide, and autologous hematopoietic stem cell support.
    Elias AD; Wheeler C; Ayash LJ; Schwartz G; Ibrahim J; Mills L; McCauley M; Coleman N; Warren D; Schnipper L; Antman KH; Teicher BA; Frei E
    Clin Cancer Res; 1998 Jun; 4(6):1443-9. PubMed ID: 9626461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of ifosfamide in combination with etoposide and cisplatin in the treatment of extensive small cell lung cancer.
    Evans WK; Stewart D; Logan D; Maroun J; Goss G; Shepherd FA; Latreille J; Warner E; Dahrouge S
    Semin Oncol; 1992 Dec; 19(6 Suppl 12):51-6. PubMed ID: 1336622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pilot study of ambulatory infusional ifosfamide admixed with carboplatin.
    Lokich JJ; Zipoli TE; Anderson NR; Moore C; Gonzalves L; Bern MM; Coco F
    Cancer; 1993 Mar; 71(6):2072-5. PubMed ID: 8443756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of non-small cell lung cancer with ifosfamide (IFO)+ 4'-epiadriamycin (EPI)+platinum vs. IFO+EPI: a GETLAC Study. Grupo de Estudio y Tratamiento Latinoamericano del Cáncer Study.
    Brocato N; Bruno MF; Araujo CE; Cervellino JC; Pirisi C; Temperley G; Sparrow C; Savulsky C; Balbiani LR
    Oncology; 1995; 52(1):24-31. PubMed ID: 7800338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.